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Abstract
Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world
due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal
expansion of strains that carry them.
Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are
macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All
dual-positive isolates are multidrug-resistant clonal lineages of Taiwan
19F-14, mostly multilocus sequence type 320,
carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae
collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.
Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to
non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits
therapy options. This upsurge could have a considerable clinical impact in Arizona.
Background
Streptococcus pneumoniae is a major etiological agent of
pneumonia, otitis media, sinusitis, and other respiratory
pathology. Macrolides remain a primary antibiotic
choice for physicians treating such infections due to
their broad spectrum of activity, patient tolerance, easy
outpatient treatment, high achievable tissue concentra-
tions, and anti-inflammatory properties. Use of macro-
lides has led to increased rates of resistance in S.
pneumoniae [1,2] and even clinical treatment failure in
several cases [3-5]. Macrolide resistance rates in clinical
isolates of S. pneumoniae vary greatly among countries
[6-9].
The main mechanisms of macrolide resistance in S.
pneumoniae also vary geographically. The erm(B)
encoded methylation of the ribosomal macrolide target
site, which confers high-level macrolide resistance as
well as resistance to lincosamides and streptogramin B
(MLSB phenotype), is the prevalent mechanism in some
Asian, European, Middle Eastern, and African countries
[6,9-13]. The mef encoded efflux pump conferring low-
level macrolide resistance (M phenotype) is more preva-
lent in other Asian and European countries and North
America [9,14-16].
S. pneumoniae clones carrying both genes (dual-posi-
tive) have emerged as important clinical populations.
These strains have serotypes not covered by the hepta-
valent pneumococcal conjugate vaccine (PCV7) released
in 2000 and are multidrug resistant, posing a significant
health threat. [9,10,15,17,18]. These dual-positive S.
pneumoniae strains now comprise a substantial portion
of macrolide resistant isolates in regions across the
globe [6,7,9,11,19].
A primary vehicle for lateral transfer of both genes is
Tn2010, a transposon of the tetracycline resistance gene
tet(M)-carrying Tn916 family with an inserted erm(B)
element and mef(E)-containing mega element [20]. A
second transposon carrying both erm(B)and mef(E),
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Tn917 and the mega element inserted, was found in a
Hungarian isolate from 2003 [21]. Tn916-family trans-
posons with various insertions are the basis of most erm
(B)-carrying mobile genetic elements, while mef(E) is
known to be only in variants of the mega element [20].
In this study, we characterize a set of macrolide resis-
tant S. pneumoniae clinical isolates collected in Arizona
based on mef(E) and erm(B) gene presence, multilocus
sequence typing (MLST) and serotyping, antibiotic sus-
ceptibility profiles, and potential transposon carriage.
We document likely episodes of capsule switching and
serotype replacement, both mechanisms that allow S.
pneumoniae to evade the PCV7 and cause infection in
an immunized population.
Methods
Bacterial isolates
From 1999 to 2008, 592 S. pneumoniae isolates were
collected by a large hospital reference laboratory that
receives specimens from ten system-wide medical cen-
ters and a high volume private reference laboratory that
receives specimens from regional inpatient, long-term
care, and outpatient facilities. Isolates considered non-
invasive were obtained from upper respiratory tract
(upper respiratory specimens plus sinus, nasal, and
nasopharyngeal swabs), lower respiratory tract, ear, eye,
body fluid, wound, and tissue (n = 488). Isolates consid-
ered invasive were obtained from blood (n = 100), urine
(n = 2), and cerebrospinal fluid (CSF, n = 2) specimens.
All were identified by bile solubility and optochin sus-
ceptibility testing. Patients ranged in age from 1 month
to 88 years with a median age of 19 years and mean age
of 29 1/2years.
Antimicrobial susceptibility testing
In vitro susceptibility testing followed Clinical and
Laboratory Standards Institute (CLSI) recommended
methodologies and interpretational zone of inhibition
diameter and minimal inhibitory concentration (MIC)
breakpoints [22]. Susceptibilities were determined for
most isolates for penicillin, erythromycin, clindamycin,
tetracycline, and trimethoprim-sulfamethoxazole by disk
agar-diffusion (Kirby-Bauer), manual microdilution
(MicroScan, Siemens Healthcare Diagnostics, Inc., Deer-
field, IL), or gradient strip agar diffusion (E-test, AB Bio-
disk, Stockholm, Sweden) testing.
DNA extraction
Bacterial DNA was extracted for PCR using DNeasy
Blood and Tissue Kit (Qiagen, Valencia, CA) following
manufacturer’s instructions for Gram-positive bacteria
with the addition of 200U of mutanolysin (Sigma-
Aldrich, St. Louis, MO).
Real-time PCR
Isolates were screened with commercial real-time PCR
assays to detect mef(E), mef(A), erm(B), and tet(M) (Life
Technologies, Foster City, CA). Real-time PCR was car-
ried out in 10 μL reactions containing 5 μL 2X Taqman
Universal PCR Mastermix (Life Technologies, Foster
City, CA), 0.5 μL 20X assay mix, and 0.2 ng genomic
DNA template. Screening was done on the 7900HT
(Life Technologies, Foster City, CA) using the following
thermal cycling conditions: 50°C for 2 min, 95°C for 10
min, and 40 cycles of 95°C for 15 s, 60°C for 1 min.
Multilocus sequence typing and serotyping
Multilocus sequence typing (MLST) was performed
using primer pairs described in the MLST database
http://spneumoniae.mlst.net/[23]. Allele profiles and
sequence types were also obtained from the database.
Strains differing by one of the seven MLST loci were
designated single-locus variants (SLVs).
PCR deduction of serotypes was performed on select
isolates as described at http://www.cdc.gov/ncidod/bio-
tech/strep/pcr.htm[24-27], with the addition of a pre-
viously described PCR to differentiate serotype 6A from
6B [28].
Transposon detection PCR
Primers previously described, some with slight modifica-
tions to adjust melting temperatures, were used to
detect regions of transposons known to carry antibiotic
resistance genes (Table 1). In brief, selected isolates
were subject to PCR using primers for the genes int and
xis,a n dtnpR and tnpA to detect the presence of trans-
posons in the Tn916 and Tn917 families respectively
[29]. Depending on their resistance gene profile, some
isolates positive for only Tn916 were subject to PCR
using the following primer pairs: SG1 and LTf [30] to
substantiate the presence of Tn2009 or Tn2010 with a 1
kb PCR product, EB2 [31] and TN2 [32] to confirm
Tn2010 with a 3.3 kb PCR product, and J12 and J11 to
detect and differentiate Tn6002 (3.6 kb PCR product)
from Tn6003/Tn1545 (7.9 kb PCR product) [33]. Iso-
lates positive for both transposon families were subject
to PCR using primers J12 and J11 to detect Tn3872
with an 800 bp PCR product. Amplicon presence or
absence and sizes analyzed via gel electrophoresis guided
the identification of transposon presence and type;
authors concede these are presumptions based on pub-
lished transposon maps and therefore limited data.
Results
Macrolide resistance
In our collection of 592 S. pneumoniae isolates, 140
(23.6%) are erythromycin resistant, including only 5 of
the 104 invasive isolates. Within the erythromycin
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Page 2 of 10resistant population, at least 110 (78.6%) are multidrug
resistant, defined here as resistant to antibiotics in at
least 3 different classes or 2 classes and positive for the
tet(M) gene if not tested for tetracycline susceptibility.
Of the 140 erythromycin resistant strains, 44 (31.4%)
were mef(E)-positive including three invasive isolates, 13
(9.3%) were erm(B)-positive including one invasive iso-
late, and 73 (52.1%) were dual mef(E)/erm(B)-positive
including one invasive isolate. One isolate was positive
for mef(A). Nine (6.4%) were negative for the macrolide
resistance genes and no further analyses were conducted
to determine their resistance mechanisms. Thirty-eight
of the mef(E)-positive isolates expressed the M-pheno-
type while six expressed the MLSB phenotype, manifest-
ing alternative clindamycin resistance mechanisms. All
13 erm(B)-positive isolates showed MLSB.S i x t y - e i g h to f
the dual-positive isolates showed MLSB; the remaining
five expressed the M-phenotype suggesting clindamycin
resistance is inducible or erm(B) is non-functional in
these isolates.
Ten of the 452 erythromycin susceptible isolates were
mef(E)-positive, one was erm(B)-positive, and five were
dual-positive, signifying a loss of gene function in these
isolates.
Time series
Macrolide resistance rates in our collection increased from
1999 to 2004, then stabilized through 2008 (Table 2).
Dual-positive numbers grew steadily over the 10-year
duration of the study from 39.1% to 67.5% of all macro-
lide resistant isolates. Concurrently, the proportion mef
(E)-positive fell (47.8% to 25.0%) and the proportion of
erm(B)-positive remained relatively steady until 2007-
2008 (Table 2).
According to MLST and serotype deduction, strain
dominance and diversity changed for all three popula-
t i o n so v e rt h e1 0y e a r s( T a b l e2 ,F i g u r e1 ) .T h em o s t
prevalent sequence types of the early dual-positive
population include ST271 and various single locus var-
iants (SLVs) that all belong to clonal complex (CC)
271. Through 2004, all isolates (n = 15) in this popula-
tion except the two ST320 isolates serotyped as 19 F, a
vaccine type (VT). ST320, a SLV of ST271, became
dominant in our collection more recently, and almost
exclusively by 2008. Of the 39 ST320 isolates sero-
typed, all were found to be a non-vaccine type (NVT)
serotype 19A. This is consistent with the well-docu-
mented serotype switch in S. pneumoniae isolates in
the U.S. [35,36].
Table 1 Oligonucleotides used in transposon detection
Transposon
region
Oligo
nucleotide
Sequence Amplicon
size (bp)
Transposon
presumed
present
S. pneumoniae
population screened
Reference
int gene int_for GCGTGATTGTATCTCACT 1046 Tn916 Dual-positive, erm(B)-
positive, mef(E)-positive
[29]
int_rev GACGCTCCTGTTGCTTCT [29]
xis gene xis_for AAGCAGACTGAGATTCCTA 193 Tn916 Dual-positive, erm(B)-
positive, mef(E)-positive
[29]
xis rev GCGTCCAATGTATCTATAA [29]
tnpRgene O21 CCAAGGAGCTAAAGAGGTCCC 1528 Tn917 Dual-positive, erm(B)-
positive, mef(E)-positive
[29]
O22 GTCCCGAGTCCCATGGAAGC [29]
tnpA gene O23 GCTTCCATGGGACTCGGGAC 2115 Tn917 Dual-positive, erm(B)-
positive, mef(E)-positive
[29]
O24 GCTCCCAATTAATAGGAGA [29]
Spans insert of erm
(B) elements in
Tn916
J12
d ATTCCCATTGAAGACGCAGAAGT 800 Tn3872 erm(B)-positive that are
Tn916-positive
[34]
J11
d CTACCGCACTTCGTTTGGTGTAC 3600 Tn6002 [34]
7900 Tn6003 or
Tn1545
Junction of mega
insert and Tn916
SG1 CTCACTGCACCAGAGGTGTA 1000 Tn2009 or
Tn2010
Dual-positive and mef(E)-
positivie that are Tn916-
positive
[30]
LTf GCAGAGTATACCATTCACATCGAAGTTCCAC 30]
Junction of erm(B)
element and Tn916
EB2 AGTAATGGTACTTAAATTGTTTAC 3300 Tn2010 Dual-positive that are
Tn916-positive
[31]
TN2
a GAAGTA(G/C)AAGCTAAAGATGG [32]
a Modified from original to change melt temperature or incorporate degeneracies
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population remained diverse over the time period (Table
2, Figure 1). Out of 20 total sequence types identified in
this population, only six were found in more than one
two-year period, three of those in both pre- and post-
vaccine introduction time periods. These include ST236,
serotype 19 F, the genotype of the highly dispersed Tai-
wan
19F-14 clone and likely ancestor to the CC271
lineages, ST376 of NVT 6A, and ST156, the genotype of
the Spain
9V-3 clone in which serotype switching from
Table 2 Time series of macrolide resistance gene presence, sequence types, and serotypes in S. pneumoniae clinical
isolates
Time period
1999-2000 2001-
2002
2003-2004 2005-2006 2007-2008
Macrolide-resistant S.
pneumoniae
population
Sequence
types (no.
isolates)
Serotyp
e
a (no.
tested)
No.
isolates
Sequence
types (no.
isolates)
Serotype
a
(no.
tested)
Sequence
types (no.
isolates)
Serotype
a
(no.
tested)
Sequence
types (no.
isolates)
Serotype
a
(no.
tested)
Dual mef(E)/erm(B)-
positive
271 (4) 19 F (4) 0 320
b (2) 19A (2) 320
b (19) 19A (16) 320
b (24) 19A (21)
1412
b,e (1) 19 F (1) 1396
b (2) 19 F (2) 320
b,e (2) 19A (1) 1459
b (1) NT
3039
b,g (1) 19 F (1) 271 (1) 19 F (1) 271 (2) 19 F (2) NF
b (1) 19A (1)
NF
b,c (2) 19 F (2) NT (1) 19 F (1) 1459
b (2) 19 F (1) NT
e (1) NT
NT
d (1) 19 F (1) 3039
b (1) 19 F (1)
1396
b,e (1) 19 F (1)
NF
b (3) 19 F (2)
NT (1)
Total for time period 9 (39.1%) 6 (40.0%) 31 (58.5%) 27 (67.5%)
mef(E)-positive 236
b (2) 19 F (2) 0 376 (2) 6A (2) 2705 (3) 33A/F/37
(3)
3280 (3) NT
13
g (1) NT 1186 (2) NT 1186 (3) NT 1379 (2) 6C (2)
156 (1) 6A (1) 1556 (1) NT 236
b (2) 19 F (2) 162
f (1) NT
376 (1) 6A (1) 6422 (1) NT 156 (1) 9 V (1) 199 (1) 19A (1)
384
f (1) 6B (1) NT
f (1) 6C 199 (1) 19A (1) 344 (1) NT
384
g (1) 6B (1) 558 (1) 35B (1) 1518 (1) 6B (1)
NF
g (1) NT 1379 (1) 6C (1) NF (1) 6A (1)
NT (2) NT 3065 (1) 6C (1)
NT
f (1) NT NF
f (1) 19 F (1)
NT (1) 6C (1)
NT
f (1) NT
Total for time period 11 (47.8%) 7 (46.7%) 16 (30.2%) 10 (25.0%)
erm(B)-positive 315 (2) 6B (2) 0 63 (1) 15A/15 F
(1)
63 (5) 15A/15 F
(5)
63 (2) 15A/15 F
(2)
3066
g (1) 18A/B/C/F
(1)
NT (1) 180 (1) 3 (1)
Total for time period 3 (13.1%) 2 (13.3%) 6 (11.3%) 2 (5.0%)
mef(A)-positive 1111 (1) 6C (1)
Total for time 0 0 0 0 1 (2.5%)
Total macrolide
resistant/Total no.
isolates collected
23/131
(17.6%)
0/34 (0%) 15/54
(27.8%)
53/223
(23.8%)
40/150
(26.7%)
a Serotype deduced by PCR; serotypes in bold are non-vaccine types
b Sequence type is a single locus variant of ST271
c NF, Sequence type not found in MLST database
d NT, Not typed
e Dual-positive with M-phenotype (n = 5)
f mef(E)-positive with MLSB phenotype (n = 6)
g Invasive isolate (n = 5)
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estingly, in the pre-vaccination time period, the ST156
strain is serotype 6A while the strain from the post-vac-
cination time period likely is 9 V. (PCR deduction typed
the strain as 9 V or 9 F.) The former was isolated from
a 70 year-old male who may have received the 23-valent
polysaccharide pneumococcal vaccine (PPSV) intended
for adults over 65 years old and high-risk groups, and
which covers serotype 9 V. This strain may have
switched from 9 V to 6A in response to PPSV, before
introduction of PCV7. Additionally, the mef(E)-positive
population illustrates serotype replacement. Historically
VT strains caused most pneumococcal disease, however
after 2000, more NVT strains than VT strains were
found.
In the erm(B)-positive population, serotype replace-
ment may also be evident. The early population is com-
p r i s e do ft w oS T 3 1 5 ,V T6 Bs t r a i n sa n daS T 3 0 6 6
strain, possibly VT 18 C. (This isolate typed as 18A, B,
C, or F using PCR; the Pneumococcal Molecular Epide-
miology Network [PMEN] clone database links ST3066
with serotype 18 C [37].) They were replaced in later
years by the unrelated ST63, NVT 15A or 15 F (PMEN
links ST63 with serotype 15A [37]) and ST180, NVT 3
(Table 2, Figure 1).
mef(E) and erm(B) population characteristics: Specimen
types
Many (n = 32) of the dual mef(E)/erm(B)-positive iso-
lates were from ear specimens collected after 2000
(post-PCV7) from children of vaccine age (less than five
years old after the introduction of the PCV7 in 2000).
Many (n = 32) were from respiratory specimens, only
eight of which came from children of vaccine age; most
came from adults post-PCV7. Similarly, a relatively large
proportion of isolates of the erm(B)-positive population
was from ear (n = 4) or eye (n = 3) specimens from
children of vaccine age, while most of the rest are from
adult patients. In contrast, the mef(E)-positive popula-
tion consists mostly of respiratory isolates (n = 25), and
a large fraction of these (n = 21) are from older genera-
tions. A relatively small proportion was from ear speci-
mens (n = 4) or eye specimens (n = 6) of children of
vaccine age.
mef(E) and erm(B) population characteristics: MLST,
antimicrobial resistance, transposon carriage
Analyses of genotypes of dual-positive isolates showed
little diversity within the population; seven of the 73
dual mef(E)/erm(B)-positive isolates are ST271 and the
remaining are SLVs of ST271 (Table 2). All 73 of the
Figure 1 Changes in population structure over time in dual
mef(E)/erm(B)-positive, mef(E)-positive, and erm(B)-positive S.
pneumoniae clinical isolates. No isolates positive for mef(E) or erm
(B) genes were collected in 2001-2002. ST, sequence type; NF,
sequence type not found; NT, not typed
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resistant to penicillin, erythromycin, clindamycin, and
trimethoprim-sulfamethoxazole and positive for tet(M);
five were reported clindamycin-susceptible. Thirty-three
dual-positive isolates representing all sequence types
found were analyzed for transposon carriage. All 33
were positive for the genes int and xis, and with primer
sets SG1/LTf and EB2/TN2, and negative for the genes
tnpR and tnpA, indicating carriage of Tn2010, the trans-
poson known to harbor erm(B), mef(E), and tet(M)
(Table 3). None apparently carried Tn2017. Although
the dual positive population is the largest, it exhibits the
lowest diversity of genotypes.
The erm(B)-positive population is comprised of strains
of four distinct sequence types, none of which match
any from the dual-positive population (Table 2). Only
one MLST allele is common to both populations.
Despite MLST dissimilarity among the erm(B)-positive
isolates, all have similar antibiotic susceptibility profiles.
Most are intermediately or fully susceptible to penicillin
and trimethoprim-sulfamethoxazole while resistant to
erythromycin and clindamycin, and all carry tet(M). Out
of the 13 isolates in this population, all eight ST63 iso-
lates were negative for int, xis, tnpR,a n dtnpA;t h e
genetic context of their antibiotic resistance genes
remains unknown. Two isolates, one ST3066 and a non-
typed isolate, tested positive for Tn916 and Tn917,a n d
produced an 800 bp PCR product with J12/J11 primers,
s i g n i f y i n gt h ep r e s e n c eo fT n 3872.T h et w oS T 3 1 5i s o -
lates and the ST180 isolate tested positive for Tn916,
but were negative for Tn917 and with J12/J11, possibly
indicating carriage of tet(M) in Tn916 and a separate
erm(B) element (Table 3).
Genotype analyses of the mef(E)-positive population
show high diversity with relatively even distribution.
Besides three sets of SLVs, the highest number of MLST
alleles shared by any two sequence types is three, and
no more than four isolates of the same sequence type
were identified. Many different antibiotic susceptibility
profiles were identified in this population, with no single
dominant profile. Of the 44 mef(E)-positive isolates,
eight isolates of three sequence types, ST236, a SLV of
ST236, and ST3280, were positive for int and xis,f o r
the SG1/LTf region, and for tet(M), indicating the pre-
sence of Tn2009. Five others were positive for only int
and xis and tet(M), indicating carriage of Tn916 and a
separate mega element. The absence of these transposon
PCR targets and tet(M) in the other 31 isolates suggests
they are carrying the mega element (Table 3).
Discussion
Macrolide resistance rates in clinical isolates of S. pneu-
moniae vary greatly among countries. The rate in our
collection of isolates from Arizona patients, 23.6%, is
consistent with other studies targeting S. pneumoniae in
North America [15,38].
The temporal trend in mef(E) and erm(B) prevalence
that we observed in our collection, the rise in propor-
tion dual gene-positive inversely to the proportion mef
(E)-positive, is similar to those of other non-invasive iso-
late studies [39]. Recent studies of invasive isolates have
shown low rates of dual gene carriage and multidrug
resistance [11,14,40]. Likewise, only one of the invasive
isolates we tested was dual-gene positive. These signifi-
cant differences between invasive and non-invasive iso-
late gene carriage and susceptibility profiles may arise
because macrolide-induced selection pressures on inva-
sive S. pneumoniae may be different from those on non-
invasive S. pneumoniae, due to the pharmacodynamics
of macrolide antibiotics.
Over half of our macrolide resistant S. pneumoniae
isolates are positive for both erm(B) and mef(E). All
these dual-positive strains belong to CC271, have almost
identical multidrug resistance profiles, and are likely car-
rying Tn2010. Clonal lineages of multidrug-resistant S.
pneumoniae belonging to CC271 are now distributed
worldwide and make up a significant portion of the
macrolide resistant S. pneumoniae isolates in many
regions [7,10,14,41,42]. The emergence of these clones is
at least partly a response to introduction of PCV7, in
which lineages of the successful multidrug resistant Tai-
wan
19F-14 ST236 clone acquired erm(B) and switched
serotypes in response to the selective pressures of an
immunized population [6,43]. One cosmopolitan lineage
recombined into ST320 and serotype 19A [35,36]. This
clone has afflicted Arizona children since the PCV7
release in 2000; of the 73 dual-positive isolates in our
collection, 47 are ST320, 38 of which are from children
of vaccine age. Most of these are from ear and respira-
tory specimens, an observation consistent with that of
t h eg l o b a lP R O T E K Ts t u d i e s[ 6 , 1 5 ] .T h e s ed a t ad i s p l a y
the opportunistic dominance of a few S. pneumoniae
clones in the post-PCV7 era. The pervasiveness of the
multidrug resistant phenotype poses a serious public
health concern for increased treatment failure and selec-
tion of these clones with the usage of any one of several
antibiotics.
Genotyping our collection revealed high strain diver-
sity within the mef(E)-positive population. The variety of
antibiotic susceptibility profiles and mobile genetic ele-
ments carrying mef(E) reflect the sequence type and ser-
otype diversity found in this population. These data
indicate that mef(E)-carrying S. pneumoniae are the
ancestral macrolide-resistant strains in the U.S. Serotype
replacement and a possible serotype switching event are
evident in this population; NVTs outnumber VTs in
later time periods, and ST156, the identifier of the
Spain
9V-3 clone, typed as NVT 6A. One notable
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Page 6 of 10Table 3 Mobile genetic elements carrying erm(B) and mef(E) genes and associated genotypic and phenotypic profiles
Population Dual
mef(E)/erm(B)-
Sequence
type 320
Antibiotic susceptiblity profile
a
Pen
nsEry
rCli
rTet
r/u+Sxt
r
Presumed transposon (no. isolates with same
profile tested) Tn2010 (12)
Total no. isolates of
same profile 43
320 Pen
nsEry
rCli
sTet
r/u+Sxt
r Tn2010 (1) 2
320 Pen
nsEry
rCli
rTet
u-Sxt
r Tn2010 (1) 2
271 Pen
nsEry
rCli
rTet
r/u+Sxt
r Tn2010 (5) 7
1396 Pen
rEry
rCli
rTet
ns/u+Sxt
r Tn2010 (2) 2
1396 Pen
rEry
rCli
sTet
ns/u+Sxt
r Tn2010 (1) 1
1459 Pen Ery Cli Tet Sxt Tn2010 (3) 3
3039 Pen
r/uEry
rCli
rTet
r/u+Sxt
r Tn2010 (2) 2
1412 Pen
rEry
rCli
sTet
rSxt
r Tn2010 (1) 1
NF Pen
nsEry
rCli
rTet
r/u+Sxt
r Tn2010 (5) 6
NT Pen
nsEry
rCli
rTet
r/u+Sxt
r NT 3
mef(E)-positive NT Pen
nsEry
rCli
sTet
rSxt
r NT 1
236 Pen
nsEry
rCli
sTet
r/u+Sxt
r Tn2009 (4) 4
1186 Pen
sEry
nsCli
sTet
s/u-Sxt
r mega (4) 4
1186 Pen
nsEry
rCli
sTet
u-Sxt
r mega (1) 1
1379 Pen
nsEry
rCli
sTet
sSxt
r mega (2) 2
1379 Pen
sEry
rCli
sTet
sSxt
r mega (1) 1
2705 Pen
sEry
rCli
sTet
s/u-Sxt
r mega (3) 3
3280 Pen
nsEry
rCli
sTet
r/u+Sxt
r Tn2009 (3) 3
376 Pen
nsEry
rCli
sTet
s/u-Sxt
r mega (3) 3
156 Pen
nsEry
rCli
sTet
s/u-Sxt
r mega (2) 2
199 Pen
sEry
rCli
sTet
sSxt
s mega (1) 1
199 Pen
nsEry
rCli
sTet
u-Sxt
r mega (1) 1
384 Pen
rEry
rCli
rTet
s+Sxt
r Tn916+mega (1) 1
384 Pen
rEry
rCli
sTet
rSxt
s Tn916+mega (1) 1
13 Pen
rEry
rCli
sTet
sSxt
r mega (1) 1
162 Pen
nsEry
rCli
rTet
u-Sxt
s mega (1) 1
erm(B)-positive 344 Pen
nsEry
rCli
sTet
u+Sxt
r Tn916+mega (1) 1
558 Pen
nsEry
rCli
sTet
sSxt
s mega (1) 1
1518 Pen
nsEry
rCli
sTet
sSxt
r mega (1) 1
1556 Pen
rEry
rCli
sTet
u-Sxt
r mega (1) 1
3065 Pen
sEry
rCli
sTet
u-Sxt
ns mega (1) 1
6422 Pen
rEry
rCli
sTet
rSxt
r mega (1) 1
NF Pen
rEry
rCli
sTet
sSxt
ns mega (1) 1
NF Pen
nsEry
rCli
sTet
sSxt
s mega (1) 1
NF Pen
nsEry
rCli
nsTet
u+Sxt
r Tn2009 (1) 1
NT Pen
nsEry
rCli
rTet
u+Sxt
s Tn916+mega (1) 1
NT Pen
sEry
rCli
sTet
sSxt
r mega (1) 1
NT Pen
sEry
rCli
sTet
sSxt
s mega (2) 2
NT Pen
rEry
rCli
rTet
rSxt
r Tn916+mega (1) 1
NT Pen
rEry
rCli
rTet
u-Sxt
r mega (1) 1
63 Pen
ns/uEry
rCli
rTet
r/u+Sxt
s/u erm(B) element (8) 8
315 Pen
iEry
rCli
rTet
rSxt
i Tn916 family (2) 2
3066 Pen
sEry
rCli
rTet
rSxt
s Tn3872 (1) 1
180 Pen
sEry
rCli
rTet
rSxt
s Tn916 family (1) 1
NT Pen
sEry
rCli
rTet
rSxt
s Tn3872 (1) 1
a Pen, penicillin; Ery, erythromycin; Cli, clindamycin; Tet, tetracycline; Sxt, trimethoprim-sulfamethoxazole; r, resistant; ns, nonsusceptible; s, susceptible; u,
unknown phenotype; +, positive for tet(M) by PCR; -, negative for tet(M) by PCR; NF, not found; NT, not typed
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Page 7 of 10observation of the mef(E)-positive population is that the
latest ST236 seen is 2005-2006, more evidence that this
clone acquired the erm(B) gene, and its lineages now
comprise the dual mef(E)/erm(B)-positive population.
Genotype analyses of the small erm(B)-positive popu-
lation illustrate serotype replacement. ST315, VT 6B is
not seen after 2000, while ST63, NVT 15A became
dominant [37]. These findings could be the result of
loss in ST315 or acquisition in ST63 of erm(B) and con-
sequent sampling bias, however neither strain carries
erm(B) in a Tn917-family transposon leaving the mobi-
lity of the erm(B) element in these strains unknown.
The dramatic increase in erm(B)-carrying S. pneumo-
niae isolates is important in regions where mef-carrying
isolates have historically predominated. Treatment with
macrolides is an option for patients suffering localized
infections caused by mef-carrying S. pneumoniae,a s
drug concentrations in tissues can supercede these bac-
teria’s macrolide MICs [44,45]. However, macrolide
MICs for erm(B)-carrying strains are significantly higher
than those of mef-carrying isolates [46], increasing the
need for alternative antibiotics where erm(B) predomi-
nates. It remains to be seen whether the U.S. will see
an increase in clinical failure in macrolide-treated
cases parallel to the increase in erm(B)-carrying S.
pneumoniae.
Conclusions
Our Arizona-based study supports other global studies
that illustrate the impact that PCV7 has had on the
population structure of macrolide resistant S. pneumo-
niae in non-invasive isolates, and calls attention to the
longevity of the success of particular multidrug resis-
tant clones. The vaccine has reduced morbidity and
mortality and multidrug resistance in invasive disease,
but serotype replacement and serotype switching by S.
pneumoniae has eclipsed these effects in non-invasive
disease, and may soon for invasive disease [8,35,47,48].
However, the recently released PCV13, which covers
serotypes of the newly dominant multidrug-resistant
c l o n e s ,i n c l u d i n g1 9 A ,m a yh a v ev e r yd i f f e r e n tc o n s e -
quences for S. pneumoniae population genetics. Vac-
cine response and population genetics studies are
important to our understanding of S. pneumoniae evo-
lution and strain dominance. More accessible higher
resolution technology, for example whole genome
sequencing, provides us with more information than
MLST, resistance gene profiling, targeted transposon
investigation, and serotyping combined [49]. Conse-
quently, future studies that include next generation
sequencing would help to better and more quickly elu-
cidate the effects of S. pneumoniae infection prevention
and treatment strategies.
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